Frank Thomas
President at ORCHARD THERAPEUTICS PLC
Net worth: 15 180 $ as of 2024-03-30
Profile
Frank E.
Thomas is currently an Independent Director at Spero Therapeutics, Inc., a Director at Orchard Therapeutics North America, an Independent Director at Larimar Therapeutics, Inc., the Chief Financial & Business Officer at Orchard Therapeutics (Europe) Ltd., and the President, Chief Operating & Financial Officer at Orchard Therapeutics Plc.
In the past, Mr. Thomas served as the President, Chief Executive Officer & Director at Critical Therapeutics, Inc., the Controller & Finance Director at Mechanical Dynamics, Inc., an Independent Director at Zafgen, Inc., a Director at Massachusetts Biotechnology Council, the Chief Financial Officer & VP-Investor Relations at Esperion Therapeutics, Inc., the Chief Operating Officer & Senior Vice President at Molecular Biometrics, Inc., and a Principal at Arthur Andersen LLP.
Mr. Thomas also held the position of President & Chief Operating Officer at AMAG Pharmaceuticals, Inc. .
Mr. Thomas obtained his undergraduate degree from the University of Michigan.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
2024-02-13 | 2,000 ( 0.00% ) | 15 180 $ | 2024-03-30 | |
SPERO THERAPEUTICS, INC.
-.--% | 2024-03-07 | 0 ( -.--% ) | - $ | 2024-03-30 |
Frank Thomas active positions
Companies | Position | Start |
---|---|---|
SPERO THERAPEUTICS, INC. | Director/Board Member | 2017-09-05 |
ORCHARD THERAPEUTICS PLC | President | 2020-03-17 |
LARIMAR THERAPEUTICS, INC. | Director/Board Member | 2020-05-27 |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | Director of Finance/CFO | 2017-12-31 |
Former positions of Frank Thomas
Companies | Position | End |
---|---|---|
AMAG PHARMACEUTICALS, INC. | Chief Executive Officer | 2012-05-13 |
Massachusetts Biotechnology Council
Massachusetts Biotechnology Council Miscellaneous Commercial ServicesCommercial Services Massachusetts Biotechnology Council is a premier life sciences and healthcare hub with over 1,600 members dedicated to preventing, treating, and curing diseases through transformative science and technology. The non-profit company is based in Cambridge, MA. MassBio works to advance policy and promote education while providing member programs, events, industry information, and services. The company's mission is to advance Massachusetts' leadership in the life sciences to grow the industry, add value to the healthcare system, and improve patient lives. Founded in 1985 by James P. Sherblom, the CEO is Kendalle Burlin O'Connell. | Director/Board Member | 2014-12-31 |
Molecular Biometrics, Inc.
Molecular Biometrics, Inc. Miscellaneous Commercial ServicesCommercial Services Molecular Biometrics, Inc. used to develop analytical methodologies for molecular diagnostic. It developed highly specific and sensitive analytical methodologies for molecular diagnostic and monitoring applications in medicine, and for drug discovery and development through pharmacodiagnostics. The company was founded in 2005 and was headquartered in Norwood, MA. | Director of Finance/CFO | 2010-01-17 |
Critical Therapeutics, Inc. | Chief Executive Officer | 2008-03-30 |
ESPERION THERAPEUTICS, INC. | Director of Finance/CFO | 2004-03-31 |
Training of Frank Thomas
University of Michigan | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 3 |
---|---|
ESPERION THERAPEUTICS, INC. | Health Technology |
SPERO THERAPEUTICS, INC. | Health Technology |
LARIMAR THERAPEUTICS, INC. | Health Technology |
Private companies | 9 |
---|---|
Mechanical Dynamics, Inc.
Mechanical Dynamics, Inc. Information Technology ServicesTechnology Services Part of Hexagon AB, Mechanical Dynamics, Inc. develops, markets, and supports virtual prototyping solutions. The private company is based in Ann Arbor, MI. The company was founded by Michael E. Korybalski. Mechanical Dynamics was acquired by MSC Software Corp., part of Hexagon AB from April 26, 2017 on May 14, 2002 for $117 million. | Technology Services |
Critical Therapeutics, Inc. | Health Technology |
Molecular Biometrics, Inc.
Molecular Biometrics, Inc. Miscellaneous Commercial ServicesCommercial Services Molecular Biometrics, Inc. used to develop analytical methodologies for molecular diagnostic. It developed highly specific and sensitive analytical methodologies for molecular diagnostic and monitoring applications in medicine, and for drug discovery and development through pharmacodiagnostics. The company was founded in 2005 and was headquartered in Norwood, MA. | Commercial Services |
Zafgen, Inc.
Zafgen, Inc. BiotechnologyHealth Technology Zafgen, Inc. is a biopharmaceutical company, which engages in the development of novel therapies for patients affected by complex metabolic diseases. It focuses on the study of MetAP2 inhibitors in both common and rare metabolic disorders. The firm also advancing programs for type 2 diabetes, Prader-Willi syndrome, and liver diseases. The company was founded on November 22, 2005 and is headquartered in Boston, MA. | Health Technology |
Arthur Andersen LLP
Arthur Andersen LLP Miscellaneous Commercial ServicesCommercial Services Arthur Andersen LLP used to provide accounting services. It was also into consulting services for clients that operate businesses throughout the United States and around the world. Arthur Andersen was founded in 1913 and was headquartered in Chicago, IL. | Commercial Services |
Massachusetts Biotechnology Council
Massachusetts Biotechnology Council Miscellaneous Commercial ServicesCommercial Services Massachusetts Biotechnology Council is a premier life sciences and healthcare hub with over 1,600 members dedicated to preventing, treating, and curing diseases through transformative science and technology. The non-profit company is based in Cambridge, MA. MassBio works to advance policy and promote education while providing member programs, events, industry information, and services. The company's mission is to advance Massachusetts' leadership in the life sciences to grow the industry, add value to the healthcare system, and improve patient lives. Founded in 1985 by James P. Sherblom, the CEO is Kendalle Burlin O'Connell. | Commercial Services |
AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. Its products include Makena and Feraheme. It focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It also manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. The company was founded on November 9, 1981 and is headquartered in Waltham, MA. | Health Technology |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | Health Technology |
Orchard Therapeutics Plc
Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
- Stock Market
- Insiders
- Frank Thomas